Edgewise Therapeutics, Inc. (EWTX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Boulder, CO, アメリカ. 現CEOは Kevin Koch.
EWTX を有する IPO日 2021-03-26, 117 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.56B.
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for musculoskeletal diseases, particularly rare genetic muscle disorders. The company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy, and has completed Phase 1 clinical trials. Edgewise is building a pipeline of precision medicine candidates that target key muscle proteins and modulators to treat genetically defined muscle disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company is advancing innovative therapeutic approaches for patients with serious muscle-wasting conditions.
